Roche bulks up in inflammation with €380m Inflazome acquisitionRoche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory diseases, buying Irish biotech Share XRoche bulks up in inflammation with €380m Inflazome acquisitionhttps://pharmaphorum.com/news/roche-bulks-up-in-inflammation-with-e380m-inflazome-acquisition/
2nd Inflammasome Therapeutics SummitTargeting the Inflammasome Share X2nd Inflammasome Therapeutics Summithttps://pharmaphorum.com/events/2nd-inflammasome-therapeutics-summit/